Announcement • Jan 08
Indivior PLC Provides Earnings Guidance for the Full Year 2026 Indivior PLC provided earnings guidance for the full year 2026. For the year, the company expects Total Net Revenue in the range of $1,125 million to $1,195 million. Board Change • Jan 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Tony Kingsley was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Nov 04
Indivior Presents New Real-World Evidence At AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine Indivior PLC presented three new scientific posters at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference last week, showcasing real-world evidence on the clinical and economic impact of monthly injectable buprenorphine in the treatment of OUD. The data highlights the potential of SUBLOCADE to improve patient outcomes while reducing healthcare resource utilization across both Medicaid and commercially insured populations. Healthcare resource utilization among patients with OUD insured by Medicaid and treated with monthly injectable bupren Morphine: a retrospective claims analys is Medicaid patients with high adherence to SUBLOCADE, a monthly injectable buprenine, had significantly lower healthcare resource utilization compared to patients with low adherence, including: Lower rates of emergency department visits for any reason (48.3% vs. 65.9%) and OUD-related reasons (3.8% vs. 12.9); Lower rates of hospital admissions for any reason (7.7% vs. 18.2%) and for OUD- related reasons (0.1% vs. 0.5); Lower rates of detox visits for any reason (9.3% vs. 28.4%) and for OUD-related reasons (7.7% against. 26.5); Lower rates of OUD symptom recurrence (7.6% vs. 27.6%). Patients who had low adherence to SUBLOCADE remained, on average, 50% associated to treatment with any combination of buprenorphine and/or naltrexone formulations. A parallel analysis among commercially insured patients also showed that higher adherence to SUBLOCADE was associated with improved healthcare resource utilization compared to low adherence, including: Fewer emergency room visits for any reason (24.2% vs. 38.9); Fewer detox visits (9.6% vs. 20.4); Reduced recurrence of OUD symptoms (5.7% vs. 16.7); and Nearly half the total medical costs ($23,051 vs. $43,357) and OUD-related costs ($8,975 vs. $19,623) after excluding medications for OUD-related pharmacy costs. These findings demonstrate that SUBLOCADE may offer meaningful value to payors by reducing all-cause and OUD-related healthcare resource utilization and costs. A retrospective cohort study found that patients treated with SUBLOCADE experienced larger reductions in the incidence of acute skin infections (37% lower based on unweighted analysis) and bacteremia (62% lower based on weighted analysis) compared to those treated with transmucosal buprenorphine. SUBLOCADE was also associated with reductions in sexually transmitted infection-related outpatient visits (77% lower based on weighted analysis). Increased hepatitis B, hepatitis C, and bone/joint infection outpatient visits among patients treated with SUBLOCade may suggest an overall improvement in the chronic management of infectious conditions through regular clinical follow-ups. Study limitations include the retrospective nature of the Electronic Health Record (EHR) and claims data, which may introduce bias, the absence of adjustments for baseline differences between adherence groups, and the inclusion of study periods overlapping with the study periods overlapping with the study period. Announcement • Oct 30
Indivior PLC Raises Earnings Guidance for the Year 2025 Indivior PLC raised earnings guidance for the year 2025. For the year, company expected Net Revenue (NR) to be in range of $1,180 million to $1,220 million against prior guidance of $1,030 million to $1,080 million . Announcement • Oct 17
Indivior PLC to Report Q3, 2025 Results on Oct 30, 2025 Indivior PLC announced that they will report Q3, 2025 results at 7:00 AM, US Eastern Standard Time on Oct 30, 2025 Announcement • Oct 15
Indivior PLC Publishes Completes Results from a Multicenter, Open-Label Clinical Trial Published in JAMA Network Open Indivior PLC published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two approaches were evaluated for initiating treatment with SUBLOCADE®?, extended-release buprenorphine, in individuals who met criteria for moderate-to-severe opioid use disorder (OUD) and who engage in high-risk opioid use--including injection use, high-dose consumption, or fentanyl use. The study found that rapid induction--administration of a single dose of 4-mg oral buprenorphine followed by a same-day SUBLOCADE injection-- was well tolerated and led to higher retention at the second injection compared to standard induction, which is at least seven days of oral buprenorphine dose adjustments prior to the first injection of SUBLOCADE. These benefits were observed across the full study population and were especially pronounced among fentanyl-positive participants, addressing the clinically relevant outcome that patients remain engaged with treatment after induction. The trial also demonstrated that administering the second SUBLOCADE injection just one week after the first was well tolerated in both treatment arms as the safety profile up to injection two was comparable, reinforcing the potential for an agile and patient-centered treatment model with rapid induction. A similar proportion of participants in adverse events up to injection two. Study limitations include its open-label design, which could introduce some reporting bias, although there was no evidence of patient and provider preference for either strategy. About SUBLOCADE®? SUBLOCADE®? (buprenorphine extended-release) injection, for subcutaneous use, CIII INDICATION and HIGHLIGHTED SAFETY information: SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously. Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements. Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be used in a manner similar to other opioids. monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors. Respiratory Depression: Life threatening respiratory depression and death have occurred in association withbuprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS disorders while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Like the drug, drug-related drug-related drug-related, SUBLOCADE injection was not only effective but also well tolerated. Announcement • Oct 01
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation Indivior PLC announced that it intends to pursue a change in domicile from the U.K. to the U.S. and will establish a new U.S. parent company, Indivior Pharmaceuticals Inc. (IPI), above its existing U.K. parent company. This follows Indivior's U.S. listing on the Nasdaq Stock Exchange ("Nasdaq") in June 2023 and subsequent cancellation of its secondary listing on the London Stock Exchange in July 2025. Indivior's board of directors is recommending the proposed change in domicile of the parent company of the Indivior group (the "Group") to maximize the benefits of its U.S. stock listing, including: Expanding Indivior's U.S. capital markets presence; Increasing potential U.S. equity indexation; Simplifying corporate governance and reducing complexity; Further positioning Indivior as a U.S. based treatment innovator, enabling closer collaboration with public health leaders on advancing SUBLOCADE®? for opioid use disorder. Transaction Process & timeline: Indivior intends to implement the redomiciliation by means of a U.K. court-sanctioned scheme of arrangement (the "Scheme"). Subject to the approval of Indivior's shareholders, following the effectiveness of the Scheme, Indivior PLC will become a direct wholly owned subsidiary of IPI, a new Delaware corporation. IPI's common stock will be listed on Nasdaq and will continue to trade under the symbol INDV. Shareholders of Indivior PLC will receive one new IPI share for each Indivior PLC share held as of the scheme record date. Indivior PLC shares will be cancelled at the time shareholders receive their new shares of IPI. No additional equity will be raised by IPI as part of the transaction. The timeline for the transaction is expected to be: Mid November 2025: Shareholder circular including the notice of EGM issued to shareholders; Early December 2025: EGM held in London; Late January 2026: Effective date of the Scheme; Indivior PLC shares exchanged for IPI shares; IPI shares begin trading on Nasdaq No action is needed by shareholders at this time. Announcement • Jul 31
Indivior PLC Revises Earnings Guidance for the Year 2025 Indivior PLC revised earnings guidance for the year 2025. For the year, the company revised net revenue to $1,030 million to $1,080 million from $955 million to $1,025 million. 
